08:00 , Jan 29, 2009 |  BC Innovations  |  Targets & Mechanisms

Breaking the biofilm barrier

Bacterial biofilms compromise the use of implanted medical devices such as stents, catheters and ventilators because they can shed bacteria and cause infection elsewhere in a patient. These surface-attached bacterial communities are very difficult to...
07:00 , Jul 9, 2007 |  BC Week In Review  |  Company News

Biosignal Ltd. management update

Biosignal Ltd. (ASX:BOS), Eveleigh, Australia   Business: Infectious   Resigned: Michael Oredsson as CEO; Head of R&D Peter Steinberg will be interim CEO; Head of Chemistry Michael Ironside will be interim R&D director  ...
07:00 , Jun 4, 2007 |  BC Week In Review  |  Company News

Biosignal management update

Biosignal Pty. Ltd. , Eveleigh, Australia   Business: Infectious   Hired: Michael Ironside as head of chemistry, formerly VP of chemical development and small scale GMP at Albany Molecular Research Inc.  ...
07:00 , May 28, 2007 |  BC Week In Review  |  Clinical News

Biosignal preclinical data

In a mouse model of E. coli infection, BOS313 plus ciprofloxacin led to a 99% reduction of E. coli in urine compared with mice receiving ciprofloxacin alone. In a separate mouse model of Pseudomonas aeruginosa,...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Company News

Biosignal board of directors update

Biosignal Pty. Ltd. (ASX:BOS), Evenleigh, Australia   Business: Infectious   Resigned: Mike Taverner  ...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

Biosignal Ltd. deal

Two doctors will use undisclosed BOS preclinical anti-bacterial compounds to develop dental devices and materials, including dentures and varnishes. BOS will own any resulting IP. The doctors, Gary Jernberg and Richard Simonsen, will fund development...
07:00 , May 22, 2006 |  BC Week In Review  |  Clinical News

Biosignal preclinical data

In a mouse model of respiratory disease, Biosignal's anti-biofilm led to 100 times better reduction of Pseudomonas aeruginosa bacteria in lungs than that with control. In addition, the anti-biofilm, which inhibits bacterial signaling associated with...
08:00 , Feb 27, 2006 |  BC Week In Review  |  Company News

Biosignal Ltd., Australian Surgical Design & Manufacture Pty Ltd, Institute for Eye Research deal

The parties partnered to develop catheters and orthopedic implants that are coated with antibacterial compounds from BOS. The institute will invest AUS$430,000 (US$318,000) in the project, while orthopedics company Australian Surgical will invest AUS$590,000 (US$436,000)....
08:00 , Dec 13, 2004 |  BC Week In Review  |  Company News

Biosignal Ltd., University of New South Wales other research news

Researchers found that furanones prevent Vibrio cholera from producing virulence factors that trigger infection and disease development. Furanones inhibit the ability of bacteria to send signals to each other, which prevent bacterial colonization. The data...
07:00 , Jun 3, 2002 |  BC Week In Review  |  Company News

Caprion management update

Caprion Pharmaceuticals Inc. , Montreal, Quebec   Business: Proteomics   Hired: Daniel Chelsky as EVP and CSO, formerly president and general manager at PerkinElmer Inc. 's BioSignal Packard Inc. division  ...